AVANIR Pharmaceuticals Invites Investors to Its First Fiscal Quarter 2

    Business Editors/Health/Medical Writers
    BIOWIRE2K

    SAN DIEGO--(BUSINESS WIRE)--Feb. 8, 2005--AVANIR Pharmaceuticals (AMEX:AVN) will webcast its quarterly conference call on Thursday, February 10, 2005, at 1:30 p.m. Pacific/4:30 p.m. Eastern. A press release announcing first fiscal quarter 2005 financial results will be issued at the close of market the same day.
    The call will be webcast live through AVANIR's corporate web site at http://www.avanir.com/, and will feature Dr. Gerald Yakatan, President and Chief Executive Officer, and Gregory P. Hanson, Vice President and Chief Financial Officer. Please go to the site at least 10 minutes early to download any applicable software.
    For those who cannot listen to the live broadcast, the online replay will be available for 90 days, and a phone replay will be available through February 17, 2005, by dialing 888-266-2081 and entering the passcode 648044.

    AVANIR Pharmaceuticals is a drug discovery and development company focused on treatments for chronic diseases. Our product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious disease. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

--30--EH/la*

CONTACT: At AVANIR Pharmaceuticals: Patrice Saxon, 858-622-5202 (Investor Relations) psaxon@avanir.com

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY EARNINGS CONFERENCE CALLS SOURCE: AVANIR Pharmaceuticals

Copyright Business Wire 2005